[ad_1]
A U.S. Meals and Drug Administration advisory committee voted versus a remedy from BrainStorm Mobile Therapeutics
BCLI,
for amyotrophic lateral sclerosis, or ALS.
The Fda panel’s vote was 17-1, with 1 adviser abstaining.
Patients previous year petitioned the Fda to contemplate the therapy, called NurOwn, in a community listening to. The agency claimed the organization submitted “scientifically incomplete” and “grossly deficient” data.
[ad_2]
Supply connection